Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
Farnier
Michel
M
Point Médical, Dijon, France.
Bortolini
Michele
M
Salko
Thomas
T
Freudenreich
Marie Odile
MO
Isaacsohn
Jonathan L
JL
Troendle
August J
AJ
Gonasun
Leonard
L
D000328:Adult; D001629:Bezafibrate / Q000009:adverse effects / Q000627:therapeutic use; D003402:Creatine Kinase / Q000097:blood* / Q000187:drug effects; D004359:Drug Therapy, Combination; D005229:Fatty Acids, Monounsaturated / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects / Q000627:therapeutic use; D000077340:Fluvastatin; D015248:Gemfibrozil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000201:enzymology; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000201:enzymology; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D005229:Fatty Acids, Monounsaturated; D000960:Hypolipidemic Agents; D007211:Indoles; D000077340:Fluvastatin; D003402:Creatine Kinase; D015248:Gemfibrozil; D011345:Fenofibrate; D001629:Bezafibrate